A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2406837121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Sarah Asemota und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163. Hauptthemen laut MEDLINE: Receptors, Androgen, Breast Neoplasms, STAT Transcription Factors, Receptors, Estrogen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute (NCI), NINDS NIH HHS.
Abstract (Originalsprache)
Cancers develop resistance to inhibitors of oncogenes mainly due to target-centric mechanisms such as mutations and splicing. While inhibitors or antagonists force targets to unnatural conformation contributing to protein instability and resistance, activating tumor suppressors may maintain the protein in an agonistic conformation to elicit sustainable growth inhibition. Due to the lack of tumor suppressor agonists, this hypothesis and the mechanisms underlying resistance are not understood. In estrogen receptor (ER)-positive breast cancer (BC), androgen receptor (AR) is a druggable tumor suppressor offering a promising avenue for this investigation. Spatial genomics suggests that the molecular portrait of AR-expressing BC cells in tumor microenvironment corresponds to better overall patient survival, clinically confirming AR’s role as a tumor suppressor. Ligand activation of AR in ER-positive BC xenografts reprograms cistromes, inhibits oncogenic pathways, and promotes cellular elasticity toward a more differentiated state. Sustained AR activation results in cistrome rearrangement toward transcription factor PROP paired-like homeobox 1, transformation of AR into oncogene, and activation of the Janus kinase/signal transducer (JAK/STAT) pathway, all culminating in lineage plasticity to an aggressive resistant subtype. While the molecular profile of AR agonist–sensitive tumors corresponds to better patient survival, the profile represented in the resistant phenotype corresponds to shorter survival. Inhibition of activated oncogenes in resistant tumors reduces growth and resensitizes them to AR agonists. These findings indicate that persistent activation of a context-dependent tumor suppressor may lead to resistance through lineage plasticity-driven tumor metamorphosis. Our work provides a framework to explore the above phenomenon across multiple cancer types and underscores the importance of factoring sensitization of tumor suppressor targets while developing agonist-like drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163.
- Molecular Bioinformatics Core, University of Tennessee Health Science Center, Memphis, TN 38163.
- Department of Surgery, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163.
- West Cancer Center and Research Institute, Memphis, TN 38120.
- Department of Pathology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163.
ORCID-Profile: Linnea Cripe, Suriyan Ponnusamy, Dong-Jin Hwang, Abhinav Jain, Duane D Miller, Lawrence M Pfeffer, Balaji Santhanam, Ramesh Narayanan
Förderung
- NCI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- NINDS NIH HHS
- HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- U.S. Department of Defense (DOD)
Zitieren
APA
Asemota, S., Effah, W., Holt, J., Johnson, D., Cripe, L., Ponnusamy, S., Thiyagarajan, T., Khosrosereshki, Y., Hwang, D. J., He, Y., Grimes, B., Fleming, M. D., Pritchard, F. E., Hendrix, A., Fan, M., Jain, A., Choi, H. Y., Makowski, L., Hayes, D. N., …, & Narayanan, R. (2024). A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2406837121
Vancouver
Asemota S, Effah W, Holt J, Johnson D, Cripe L, Ponnusamy S, et al. A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2406837121
BibTeX
@article{Asemota2024,
author = {Asemota, Sarah and Effah, Wendy and Holt, Jeremiah and Johnson, Daniel and Cripe, Linnea and Ponnusamy, Suriyan and Thiyagarajan, Thirumagal and Khosrosereshki, Yekta and Hwang, Dong-Jin and He, Yali and Grimes, Brandy and Fleming, Martin D and Pritchard, Frances E and Hendrix, Ashley and Fan, Meiyun and Jain, Abhinav and Choi, Hyo Young and Makowski, Liza and Hayes, D Neil and Miller, Duane D and Pfeffer, Lawrence M and Santhanam, Balaji and Narayanan, Ramesh},
title = {A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2406837121}
}
EUVIMED